Border Green: Cannabis Smuggling Routes Then and Now

By Susan Berry

For years, most cannabis research and product development has revolved around two “headline” cannabinoids: THC (best known for intoxication) and CBD (best known for wellness claims and non-intoxicating effects). But the cannabis plant contains many more cannabinoids—often called minor cannabinoids—that show interesting biological activity even though they appear in smaller amounts.

Two of the most talked-about right now are CBN (cannabinol) and THCV (tetrahydrocannabivarin). Researchers are paying close attention because these compounds may offer more targeted effects for specific health concerns—particularly sleep (CBN) and metabolic health like appetite and blood sugar regulation (THCV).

What are “minor cannabinoids,” really?

“Minor” doesn’t mean unimportant—it mostly means less abundant in the plant and historically less studied. Some minor cannabinoids are produced directly by the plant; others appear as cannabinoids age or degrade (for example, when exposed to light, heat, and oxygen). CBN is a well-known example because it’s often described as a product of THC oxidation over time.

Interest is growing for practical reasons: as legal markets expand and lab testing becomes more advanced, manufacturers can isolate or formulate these compounds more reliably. At the same time, researchers are trying to map out what these cannabinoids actually do in the body, at what dose, and with what risks.

CBN and Sleep: Promising, but still being pinned down

CBN is commonly marketed as a “sleep cannabinoid.” However, science is still working out how strong and consistent its effects are in humans. The overall picture is: CBN might help some people, but outcomes depend heavily on formulation, dose, and the kind of sleep problem being studied.

Why formulation matters: the “water-soluble nano” angle

One reason your source focused on a water-soluble nano form of CBN is that cannabinoids are typically fat-soluble and can be absorbed inconsistently when taken orally. Nano-emulsions and water-soluble formats are designed to improve bioavailability (how much gets absorbed) and sometimes speed up onset (how quickly effects begin). In the review you cited, the authors highlight a study where a water-soluble nano CBN product was associated with faster sleep onset and better sleep duration/quality in people with sleeplessness.

It’s important to say this clearly: some of the “nano CBN” evidence comes from smaller studies and survey-style outcomes, which are helpful for early signals but aren’t as strong as large clinical trials.

What do controlled human trials show so far?

Controlled trials are starting to fill the gap:

  1. A double-blind, randomised, placebo-controlled study (among adults who rated their sleep as poor) found that 20 mg CBN showed a non-significant but potentially meaningful improvement in sleep quality and significantly reduced the number of awakenings and overall sleep disturbance compared with placebo. However, it did not significantly change sleep onset latency (how quickly people fell asleep) or wake after sleep onset in that trial.
  2. A larger randomised trial tested different doses of a proprietary CBN product (25 mg, 50 mg, 100 mg), using a standardised sleep disturbance scale, and framed the work explicitly as addressing the reality that evidence has been limited and needs better data.
  3. Meanwhile, preclinical work continues to explore how CBN may affect sleep. A study in Neuropsychopharmacology reported that CBN (and its metabolite, 11-hydroxy-CBN) influenced sleep architecture in animal models, suggesting a mechanistic basis worth further exploration in humans.

Where that leaves us on CBN

Right now, the most honest summary is:

  1. CBN is plausible for sleep support, especially around sleep maintenance (waking during the night), and possibly sleep quality for some people.
  2. But the field still needs more studies using objective measures (like polysomnography or validated wearables), clearer comparisons across formulations (standard oils vs nano/water-soluble), and stronger data on next-day effects and long-term use.

THCV and Metabolic Health: Appetite and blood sugar are the big themes

THCV is often described online as “diet weed,” but the scientific interest goes deeper than that. THCV interacts with cannabinoid receptors differently from THC, and researchers have been investigating it for its potential influence on appetite, body weight regulation, and glycemic control (blood sugar).

Evidence in humans: type 2 diabetes research

One of the most-cited human studies is a randomised, double-blind, placebo-controlled pilot trial in people with type 2 diabetes, which concluded that THCV could represent a new therapeutic agent in glycemic control (though, as a pilot study, it’s not the final word).

More recent reviews continue to discuss THCV as a promising compound for metabolic disorders, while emphasising that we still need larger, longer, well-powered trials to confirm real-world outcomes, such as sustained weight changes and clinically meaningful glucose improvements, across diverse populations.

Why THCV is being treated as “therapeutic potential,” not a guaranteed solution

Metabolic disorders like obesity and type 2 diabetes are influenced by many factors: diet, activity, sleep, stress, genetics, medication, and more. THCV is being explored as a possible tool, not a replacement for standard care. The best research framing right now is: THCV may eventually support metabolic regulation, but it’s too early to treat it like a proven weight-loss or diabetes treatment.

Beyond CBN and THCV: why minor cannabinoids are a big research frontier

The reason the research community keeps circling back to minor cannabinoids is that the “cannabinome” is large, and many compounds may have narrower, more specific effects than THC. Reviews highlight potential areas such as nausea, mood disorders, neuropathic pain, inflammation, and neuroprotection—but the recurring theme is that the evidence is often patchy and sometimes mostly preclinical.

This is why high-quality review papers describe minor cannabinoids as “promising,” while also stressing that much of the work is still early-stage and needs better translational research (moving from lab findings to reliable patient outcomes).

Safety, quality, and “label reality”

One practical issue matters as much as the science: product consistency. Minor cannabinoid products can vary widely in dose accuracy, purity, and whether they contain additional cannabinoids (including THC). That matters for:

  1. Side effects (sedation, dizziness, dry mouth, appetite changes)
  2. Drug interactions (especially if someone is on sedatives, antidepressants, diabetes medication, or blood thinners)
  3. Workplace testing (trace THC can be a risk)

Clinical researchers repeatedly emphasise the need for better standards and stronger evidence on dosing and safety over time.

The bottom line

Minor cannabinoids like CBN and THCV are becoming major conversation points because early evidence suggests real therapeutic potential—CBN for aspects of sleep (including sleep disturbance and awakenings), and THCV for metabolic health markers such as blood sugar regulation.

But the current state of the science is best described as promising rather than proven. Much of the research is still developing, and the next big leap will come from larger trials that compare formulations (including water-soluble nano products), confirm objective outcomes, and clarify long-term safety.

If you’d like, I can also adapt this into your Rolling Stoner format with SEO pack (keyphrase, meta title/description, slug, tags) and a short sidebar “Quick Tips” box for readers.